Clinical bottom line
Inhaled sodium-glucose cotransporter-2 (SGLT2) inhibitors represent an emerging therapeutic approach under investigation for pulmonary hypertension (PH) associated with heart failure (HF). While oral SGLT2 inhibitors have demonstrated benefits in reducing HF hospitalizations and improving cardiovascular outcomes, their inhaled formulations aim to target pulmonary vascular pathology more directly, potentially improving pulmonary hemodynamics with fewer systemic effects. Current evidence remains preliminary and largely preclinical or extrapolated from systemic SGLT2 inhibitor studies. Clinicians should consider inhaled SGLT2 inhibitors as a putative, hypothesis-generating treatment modality that warrants further clinical validation before routine use in managing PH secondary to HF.
What the evidence shows
SGLT2 inhibitors, originally developed for glycemic control in diabetes, have gained prominence for their cardiovascular and renal protective effects, particularly in heart failure with reduced ejection fraction (HFrEF) (Memon et al., 2025; Mekala et al., 2023). These agents reduce HF hospitalizations and mortality by mechanisms beyond glucose lowering, including natriuresis, improved myocardial metabolism, and anti-inflammatory effects (Butler et al., 2024; Nandave et al., 2024).
Pulmonary hypertension complicating HF is a common and prognostically adverse condition characterized by elevated pulmonary vascular resistance and right ventricular strain (Pearce et al., 2023). Traditional management focuses on optimizing HF therapy and addressing pulmonary vascular remodeling. However, targeted pulmonary vasodilators have limited efficacy in PH due to left heart disease.
Inhaled SGLT2 inhibitors are proposed to deliver the drug directly to the pulmonary vasculature, potentially enhancing local vasodilatory and anti-remodeling effects while minimizing systemic exposure and adverse effects (Memon et al., 2025). Preclinical models suggest that SGLT2 inhibition may attenuate pulmonary vascular remodeling and improve endothelial function, which could translate into improved pulmonary hemodynamics in HF-associated PH (Nandave et al., 2024).
Clinical data specifically evaluating inhaled SGLT2 inhibitors in PH secondary to HF are currently lacking. Most clinical evidence derives from oral SGLT2 inhibitor trials in HF populations, which have not systematically assessed pulmonary vascular endpoints (Butler et al., 2024; Mekala et al., 2023). Nonetheless, the mechanistic rationale and early translational studies support further exploration of inhaled formulations as a novel therapeutic avenue.
Caveats and uncertainty
The role of inhaled SGLT2 inhibitors in PH associated with HF remains investigational. No large-scale randomized controlled trials have yet evaluated their safety, efficacy, or optimal dosing in this indication. The pharmacokinetics, pulmonary deposition, and long-term pulmonary safety of inhaled SGLT2 inhibitors require rigorous characterization.
Extrapolation from systemic SGLT2 inhibitor data is limited by differences in delivery route and target tissue exposure. Potential off-target effects, including local airway irritation or altered pulmonary immune responses, are unknown. Moreover, the heterogeneity of PH phenotypes in HF patients complicates patient selection and endpoint definition for future studies (Pearce et al., 2023).
Clinicians should be cautious in interpreting preliminary data and avoid off-label use of inhaled SGLT2 inhibitors until robust clinical evidence emerges. Current HF guidelines do not endorse inhaled SGLT2 inhibitors for PH management (Butler et al., 2024).
How this may change practice
If ongoing and future studies confirm safety and efficacy, inhaled SGLT2 inhibitors could become a targeted adjunctive therapy for PH in HF, addressing an unmet need in this high-risk population. This approach may complement systemic HF therapies by directly modulating pulmonary vascular pathology, potentially improving symptoms, exercise capacity, and right ventricular function.
Inhaled delivery could reduce systemic side effects and drug interactions, facilitating use in patients with comorbidities or polypharmacy. Integration of inhaled SGLT2 inhibitors into multidisciplinary HF and PH management programs would require education on inhaler technique, monitoring protocols, and coordination with cardiopulmonary specialists.
Until such evidence is available, clinicians should continue to optimize established HF therapies and consider referral to PH centers for comprehensive evaluation and management.